
CITY THERAPEUTICS, INC.
CTYPricedCITY THERAPEUTICS, INC. · Nasdaq Global Market · Research source · 424B4 · 2026-10-16 · Latest filing · 8-K · 2026-11-10 SEC ↗
City Therapeutics prices a clinical-stage RNAi IPO with substantial dilution and development-financing dependence.
As of the October 15, 2026 prospectus, City Therapeutics proposed an 11,111,111-share IPO at $18.00 per share; delivery was expected around October 19, 2026, not confirmed completed in the supplied evidence.
- Business and development direction
CITY THERAPEUTICS, INC.
Current business Future development
Key risks
Risk 1
The company has a limited operating history and no commercially approved products.
Risk 2
Clinical results may fail to demonstrate safety or efficacy or replicate preclinical results.
Risk 3
Third-party research, trial, supply and manufacturing performance may delay development.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Offering quality | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
| # | Institution | Underwriting allocation | Ratio · calculated | Shares |
|---|---|---|---|---|
| 1 | Goldman Sachs & Co. LLC | 41.00% | 4,555,556 shares | |
| 2 | Jefferies LLC | 35.00% | 3,888,889 shares | |
| 3 | Stifel, Nicolaus & Company, Incorporated | 18.00% | 2,000,000 shares | |
| 4 | Oppenheimer & Co. Inc. | 6.00% | 666,666 shares |
Ratio = institution commitment ÷ complete source-table total (11,111,111 shares) × 100.
Underwriting terms
| Measure | Reported value | Unit |
|---|---|---|
| Underwriting discount per share | $1.26 | $ / share |
| Total underwriting discount | $14,000,000 | $ |
Source and calculation
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 3; source 5863:12752; SHA256 e44613efdd3fedb83b69263d742e5e267a55e90b4a479306de37cf4c6a8000e7 ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 3; source 5863:12752; SHA256 e44613efdd3fedb83b69263d742e5e267a55e90b4a479306de37cf4c6a8000e7 ↗IPO CAPITAL QUALITY
Basis and evidence
424B4 · 2026-10-16
As of the October 15, 2026 prospectus, City Therapeutics proposed an 11,111,111-share IPO at $18.00 per share; delivery was expected around October 19, 2026, not confirmed completed in the supplied evidence.
Offering structure
| Measure | Reported value | Unit |
|---|---|---|
| Primary shares | 11,111,111 | Shares |
| Offering price | $18 | $ / share |
| Gross offering amount | $199,999,998 | $ |
Source and calculation
Shares offered by issuer Reported inputs; each row retains its own source basis.
Shares offered by issuer
Cover and opening disclosure ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 2; source 5863:12752; SHA256 e44613efdd3fedb83b69263d742e5e267a55e90b4a479306de37cf4c6a8000e7 ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 2; source 5863:12752; SHA256 e44613efdd3fedb83b69263d742e5e267a55e90b4a479306de37cf4c6a8000e7 ↗Proceeds and intended uses
| Measure | Reported value | Unit |
|---|---|---|
| Issuer proceeds before expenses | $185,999,998 | $ |
Source and calculation
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 4; source 5863:12752; SHA256 e44613efdd3fedb83b69263d742e5e267a55e90b4a479306de37cf4c6a8000e7 ↗Dilution and valuation
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Base post-offer valuation | ≈ 51.7212M | ≈ $930.981M | |
| Post-offer shares — base/no option | 51,721,168 | — | |
| Post-offer shares — full option | 53,387,834 | — | |
| Offering price | — | $18 | |
| Gross offering amount | — | $199,999,998 |
Basis and evidence ↗
Prospectus share summary; Common stock to be outstanding immediately after this offering; 51,721,168 shares (or 53,387,834 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Prospectus share summary; Common stock to be outstanding immediately after this offering; 51,721,168 shares (or 53,387,834 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 51,721,168 shares (or 53,387,834 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Exact input · Offering price: $18
Exact input · Post-offer shares — base/no option: 51,721,168
Prospectus share summary; Common stock to be outstanding immediately after this offering; 51,721,168 shares (or 53,387,834 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Exact input · Post-offer shares — full option: 53,387,834
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 51,721,168 shares (or 53,387,834 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 51,721,168 shares (or 53,387,834 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Prospectus share summary; Common stock to be outstanding immediately after this offering; 51,721,168 shares (or 53,387,834 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 51,721,168 shares (or 53,387,834 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Exact input · Post-offer shares — base/no option: 51,721,168
Exact input · Offering price: $18
Share-count comparison
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Source ↗IPO valuation scenario simulator
Offering completion · $18 × ≈ 51.7212M shares · Final
Source and calculation ↗
Reported point prices retain their security, class, currency and per-security unit; range endpoints remain separate.
Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.
Equity value is the exact product of the selected compatible per-share price and whole-issuer post-offer count.
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.
The exact selected base supports transparent hypothetical price/share changes; it is not a forecast or tradable float.
The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.
$18 × 51,721,168 = $930,981,024 [summary-columns-143350-base-price, summary-columns-143350-base-post]
Exact calculation · Derived whole-issuer equity value: $930,981,024
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Ownership across stages | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
- As of
- 2026-10-16
Relationship filters
Select for details · CITY THERAPEUTICS, INC.
Holdings and voting rights
Holder groups may overlap; these rows are not an additive ownership partition.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| ARCH Venture Fund XII, L.P.Beneficial shares | 13,522,507 | — | — | Shares of Common Stock Beneficially Owned |
| Invus Public Equities, L.P.Beneficial shares | 3,227,866 | — | — | Shares of Common Stock Beneficially Owned |
| FMR LLCBeneficial shares | 3,863,783 | — | — | Shares of Common Stock Beneficially Owned |
| Entities Affiliated with VikingBeneficial shares | 2,027,005 | — | — | Shares of Common Stock Beneficially Owned |
| Andrew (Andy) Orth, M.B.A. (5) President, Chief Executive Officer and DirectorBeneficial shares | 1,094,544 | — | — | Shares of Common Stock Beneficially Owned |
| Baisong Mei, M.D., Ph.D. (6) Chief Medical OfficerBeneficial shares | 234,678 | — | — | Shares of Common Stock Beneficially Owned |
| Tracy Zimmermann, Ph.D. (7) Chief Scientific OfficerBeneficial shares | 269,569 | — | — | Shares of Common Stock Beneficially Owned |
| John Maraganore, Ph.D.Beneficial shares | 2,121,831 | — | — | Shares of Common Stock Beneficially Owned |
| Barry GreeneBeneficial shares | 31,186 | — | — | Shares of Common Stock Beneficially Owned |
| Saraswathy (Sara) V. Nochur, Ph.D.Beneficial shares | 27,443 | — | — | Shares of Common Stock Beneficially Owned |
| Ron PhilipBeneficial shares | 33,680 | — | — | Shares of Common Stock Beneficially Owned |
| All executive officers and directors as a group (10 persons)Beneficial shares | 4,355,351 | — | — | Shares of Common Stock Beneficially Owned |
| ARCH Venture Fund XII, L.P.Beneficial ownership | — | 34.96%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| ARCH Venture Fund XII, L.P.Beneficial ownership | — | 26.03%Beneficial | — | Percentage of Shares Beneficially Owned; After Offering |
| Invus Public Equities, L.P.Beneficial ownership | — | 8.35%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Invus Public Equities, L.P.Beneficial ownership | — | 6.21%Beneficial | — | Percentage of Shares Beneficially Owned; After Offering |
| FMR LLCBeneficial ownership | — | 9.99%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| FMR LLCBeneficial ownership | — | 7.44%Beneficial | — | Percentage of Shares Beneficially Owned; After Offering |
| Entities Affiliated with VikingBeneficial ownership | — | 5.24%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Entities Affiliated with VikingBeneficial ownership | — | 3.9%Beneficial | — | Percentage of Shares Beneficially Owned; After Offering |
| Andrew (Andy) Orth, M.B.A. (5) President, Chief Executive Officer and DirectorBeneficial ownership | — | 2.83%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Andrew (Andy) Orth, M.B.A. (5) President, Chief Executive Officer and DirectorBeneficial ownership | — | 2.11%Beneficial | — | Percentage of Shares Beneficially Owned; After Offering |
| John Maraganore, Ph.D.Beneficial ownership | — | 5.48%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| John Maraganore, Ph.D.Beneficial ownership | — | 4.08%Beneficial | — | Percentage of Shares Beneficially Owned; After Offering |
| All executive officers and directors as a group (10 persons)Beneficial ownership | — | 11.14%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| All executive officers and directors as a group (10 persons)Beneficial ownership | — | 8.32%Beneficial | — | Percentage of Shares Beneficially Owned; After Offering |
| Our executive officers, directors, five percent stockholders and their affiliatesOwnership as disclosed | — | approximately 69.1%Beneficial | — | Source statement; approximately ; source predicate: beneficially own; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options and without giving effect to (i) any purchases by such persons in this offering or (ii) options granted to certain of our employee; source scope: of our common stock and, upon closing of this offering, that same group will beneficially own approximately; not an additive ownership partition |
| Our executive officers, directors, five percent stockholders and their affiliatesOwnership as disclosed | — | approximately 51.5%Beneficial | — | Source statement; approximately ; source predicate: will beneficially own; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options and without giving effect to (i) any purchases by such persons in this offering or (ii) options granted to certain of our employee; source scope: of our outstanding common stock (assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options and without giving effect to (i) any purchases b; not an additive ownership partition |
| Venture Fund XII, L.P.Ownership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| Invus Public Equities, L.P.Ownership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| FidelityOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| VikingOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| common stockper-share voting rights | — | — | 1 vote per shareVotes per share | Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicable |
Source and calculation ↗
Exact source ownership column: Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares of Common Stock Beneficially Owned; source holder: ARCH Venture Fund XII, L.P.(1)
Exact source ownership column: Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares of Common Stock Beneficially Owned; source holder: Invus Public Equities, L.P.(2)
Exact source ownership column: Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares of Common Stock Beneficially Owned; source holder: FMR LLC(3)
Exact source ownership column: Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares of Common Stock Beneficially Owned; source holder: Entities Affiliated with Viking(4)
Exact source ownership column: Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares of Common Stock Beneficially Owned; source holder: Andrew (Andy) Orth, M.B.A. (5) President, Chief Executive Officer and Director
Exact source ownership column: Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares of Common Stock Beneficially Owned; source holder: Baisong Mei, M.D., Ph.D. (6) Chief Medical Officer
Exact source ownership column: Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares of Common Stock Beneficially Owned; source holder: Tracy Zimmermann, Ph.D. (7) Chief Scientific Officer
Exact source ownership column: Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares of Common Stock Beneficially Owned; source holder: John Maraganore, Ph.D.(8)
Exact source ownership column: Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares of Common Stock Beneficially Owned; source holder: Barry Greene(9)
Exact source ownership column: Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares of Common Stock Beneficially Owned; source holder: Saraswathy (Sara) V. Nochur, Ph.D.(10)
Exact source ownership column: Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares of Common Stock Beneficially Owned; source holder: Ron Philip(11)
Exact source ownership column: Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares of Common Stock Beneficially Owned; source holder: All executive officers and directors as a group (10 persons) (12)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: ARCH Venture Fund XII, L.P.(1)
Exact source ownership column: Percentage of Shares Beneficially Owned; After Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; After Offering; source holder: ARCH Venture Fund XII, L.P.(1)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Invus Public Equities, L.P.(2)
Exact source ownership column: Percentage of Shares Beneficially Owned; After Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; After Offering; source holder: Invus Public Equities, L.P.(2)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: FMR LLC(3)
Exact source ownership column: Percentage of Shares Beneficially Owned; After Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; After Offering; source holder: FMR LLC(3)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Entities Affiliated with Viking(4)
Exact source ownership column: Percentage of Shares Beneficially Owned; After Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; After Offering; source holder: Entities Affiliated with Viking(4)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Andrew (Andy) Orth, M.B.A. (5) President, Chief Executive Officer and Director
Exact source ownership column: Percentage of Shares Beneficially Owned; After Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; After Offering; source holder: Andrew (Andy) Orth, M.B.A. (5) President, Chief Executive Officer and Director
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: John Maraganore, Ph.D.(8)
Exact source ownership column: Percentage of Shares Beneficially Owned; After Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; After Offering; source holder: John Maraganore, Ph.D.(8)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: All executive officers and directors as a group (10 persons) (12)
Exact source ownership column: Percentage of Shares Beneficially Owned; After Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; After Offering; source holder: All executive officers and directors as a group (10 persons) (12)
Source statement; approximately ; source predicate: beneficially own; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options and without giving effect to (i) any purchases by such persons in this offering or (ii) options granted to certain of our employee; source scope: of our common stock and, upon closing of this offering, that same group will beneficially own approximately; not an additive ownership partition
Our executive officers, directors, five percent stockholders and their affiliates beneficially own approximately 69.1% of our common stock and, upon closing of this offering, that same group will beneficially own approximately 51.5% of our outstanding common stock (assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options and without giving effect to (i) any purchases by such persons in this offering or (ii) options granted to certain of our employees and non-employee directors upon pricing of this offering). Therefore, even after this offering, these stockholders will have the ability to influence us through their ownership positions. For example, these stockholders, acting together, may be able to exert significant influence over matters such as elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.
Source statement; approximately ; source predicate: will beneficially own; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options and without giving effect to (i) any purchases by such persons in this offering or (ii) options granted to certain of our employee; source scope: of our outstanding common stock (assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options and without giving effect to (i) any purchases b; not an additive ownership partition
Our executive officers, directors, five percent stockholders and their affiliates beneficially own approximately 69.1% of our common stock and, upon closing of this offering, that same group will beneficially own approximately 51.5% of our outstanding common stock (assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options and without giving effect to (i) any purchases by such persons in this offering or (ii) options granted to certain of our employees and non-employee directors upon pricing of this offering). Therefore, even after this offering, these stockholders will have the ability to influence us through their ownership positions. For example, these stockholders, acting together, may be able to exert significant influence over matters such as elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
Robert Nelsen, M.B.A. serves as a member of our board of directors and is an affiliate of ARCH Venture Partners, of which Venture Fund XII, L.P. is an affiliated fund. Venture Fund XII, L.P. beneficially owns more than 5% of our outstanding capital stock.
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
Invus Public Equities, L.P. beneficially owns more than 5% of our outstanding capital stock.
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
Fidelity collectively refers to Powhatan & Co., LLC FBO Fidelity Growth Company Private Investments Portfolio LLC; Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund; Fidelity Mt. Vernon Street Trust: Fidelity Growth Company K6 Fund; and Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund. Fidelity beneficially owns more than 5% of our outstanding capital stock.
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
Viking collectively refers to Viking Global Opportunities Illiquid Investment Sub-Master LP and Viking Global Opportunities Vintage IV (Aggregator) LP. Viking beneficially owns more than 5% of our outstanding capital stock.
Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicable
Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding convertible preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. Source context: The following description of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to the amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and the amended and restated bylaws, which became effective upon the effectiveness of the registration statement of which this prospectus forms a part. Copies of these documents have been filed with the SEC as exhibits to our registration statement, of which this prospectus forms a part. The descriptions of the common stock and preferred stock reflect changes to our capital structure that will be in effect on the completion of this offering.
Economic ownership
A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.
Share supply
Conditional lock-up duration
Lock-up period from prospectus date
| Measure | Reported value |
|---|---|
| Conditional lock-up duration | 180 days |
Source and calculation
Lock-up period from prospectus date
UNDERWRITING ↗Source lock-up conditions
Literal day restriction; source duration bound ≥; after date of this prospectus; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| We, all of our directors and officers, and the holders of substantially all of our capital stock and securities convertible into or exchangeable for our capital stock | ≥180 days |
Source and calculation
We, all of our directors and officers, and the holders of substantially all of our capital stock and securities convertible into or exchangeable for our capital stock have entered into lock-up agreements with the underwriters and/or are subject to market standoff agreements or other agreements with us, which prevents them from selling any of our common stock or any securities convertible into or exercisable or exchangeable for common stock for a period of not less than 180 days from the date of this prospectus without the prior written consent of Goldman Sachs & Co. LLC and Jefferies LLC, subject to certain exceptions. See the section titled “Underwriting” appearing elsewhere in this prospectus for more information.
SEC lock-up paragraph; source 2652654:2653745; SHA256 597d7c600bab40c0f44175fe091d9d563f0346213016780f0b17946ecf233856 ↗Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Conditional lock-up timeline | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
Financial quality
Bars compare absolute amounts within each measure. Each measure has its own scale.
Operating cash flow
$ · Annual values as reported · Consolidated| Calculation | FY2024 | FY2025 |
|---|---|---|
| Operating cash flowConsolidated | ($20,391,000) | ($41,611,000) |
| Calculation | Reported value |
|---|---|
| Cash and cash equivalents2024-12-31 · Consolidated | $126,899,000 |
| Cash and cash equivalents2025-12-31 · Consolidated | $112,793,000 |
| Current assets2024-12-31 · Consolidated | $128,902,000 |
| Current assets2025-12-31 · Consolidated | $116,873,000 |
| Total assets2024-12-31 · Consolidated | $145,353,000 |
| Total assets2025-12-31 · Consolidated | $149,768,000 |
| Current liabilities2024-12-31 · Consolidated | $20,742,000 |
| Current liabilities2025-12-31 · Consolidated | $38,042,000 |
| Total liabilities2024-12-31 · Consolidated | $30,264,000 |
| Total liabilities2025-12-31 · Consolidated | $89,909,000 |
| Total equity / (deficit)2024-12-31 · Consolidated | ($29,425,000) |
| Total equity / (deficit)2025-12-31 · Consolidated | ($84,655,000) |
| Cash and cash equivalents2025-12-31 · Consolidated · Unaudited | $112,793,000 |
| Cash and cash equivalents2026-06-30 · Consolidated · Unaudited | $169,605,000 |
| Current assets2025-12-31 · Consolidated · Unaudited | $116,873,000 |
| Current assets2026-06-30 · Consolidated · Unaudited | $175,688,000 |
| Total assets2025-12-31 · Consolidated · Unaudited | $149,768,000 |
| Total assets2026-06-30 · Consolidated · Unaudited | $208,611,000 |
| Current liabilities2025-12-31 · Consolidated · Unaudited | $38,042,000 |
| Current liabilities2026-06-30 · Consolidated · Unaudited | $64,757,000 |
| Total liabilities2025-12-31 · Consolidated · Unaudited | $89,909,000 |
| Total liabilities2026-06-30 · Consolidated · Unaudited | $84,272,000 |
| Total equity / (deficit)2025-12-31 · Consolidated · Unaudited | ($84,655,000) |
| Total equity / (deficit)2026-06-30 · Consolidated · Unaudited | ($131,717,000) |
| Operating cash flow6M ended 2025-06-30 · Consolidated · Unaudited | ($7,098,000) |
| Operating cash flow6M ended 2026-06-30 · Consolidated · Unaudited | ($43,158,000) |
Basis and evidence
Financial quality and runway
Financial quality and runway
The latest supplied full financial period was the six months ended June 30, 2026, with unaudited interim statements; a September 30 cash estimate was preliminary and unaudited. Revenue amounts, cash-flow data and debt balances were not supplied.
EvidenceFinancial review 1Net loss was $53.4 million for the six months ended June 30, 2026, versus $24.3 million for the comparable 2025 period.
+
Net loss was $53.4 million for the six months ended June 30, 2026, versus $24.3 million for the comparable 2025 period.
EvidenceFinancial review 2Net loss was $58.5 million for 2025 and $27.8 million for 2024.
+
Net loss was $58.5 million for 2025 and $27.8 million for 2024.
EvidenceFinancial review 3Accumulated deficit was $142.5 million as of June 30, 2026.
+
Accumulated deficit was $142.5 million as of June 30, 2026.
EvidenceFinancial review 4Estimated cash and cash equivalents at September 30, 2026 were approximately $141.9 million, preliminary and unaudited.
+
Estimated cash and cash equivalents at September 30, 2026 were approximately $141.9 million, preliminary and unaudited.
MATERIAL CHANGES
The latest material signals and their investor impact are shown below.
Why it mattersThe current filing increased the base primary offering.
Evidence · Cover and opening disclosureWhy it mattersThe current filing fixed the price at $18.00 rather than a $17–$19 estimate.
Evidence · Cover and opening disclosureWhy it mattersThe current filing supplied a specific expected delivery date; the prior filing left it blank.
Evidence · Cover and opening disclosure424B40001104659-26-116636 ↗
Loading filing history…
The company has a limited operating history and no commercially approved products.
- Evidence
- Risk Factors ↗
Clinical results may fail to demonstrate safety or efficacy or replicate preclinical results.
Third-party research, trial, supply and manufacturing performance may delay development.
Future financing may dilute holders, while concentrated holders may influence directors and major transactions.
- Evidence
- DILUTION ↗